{
  "abstract": "Introduction\n\nThe aim of this work is to evaluate the early real-world effectiveness, anatomical outcomes, and safety of intravitreal aflibercept 8 mg in neovascular aged-related macular degeneration (nAMD) eyes.Methods\n\nThis retrospective single-center study included consecutive nAMD eyes treated with at least one aflibercept 8-mg injection between January 2025 and January 2026 in France. Primary outcomes were treatment interval extension and macular drying. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central macula thickness (CMT), OCT biomarkers, and safety. Subgroup analyses were performed according to treatment status, responder profile, and prior anti-VEGF generation. In addition, baseline predictive factors associated with treatment interval extension, achievement of an interval ≥ 12 weeks, and dry macular status were evaluated. A sensitivity analysis was performed in eyes with ≥ 6 months of follow-up.Results\n\nA total of 338 eyes from 267 patients were included (82 treatment-naïve and 256 switched eyes), with a mean follow-up duration of 5.5 ± 3.3 months. In switched eyes, the mean treatment interval increased by +1.8 ± 2.4 weeks (p < 0.001), with significant gains in good responders (+ 2.7 weeks), frequent flyers (+ 0.7 weeks), and poor responders (+ 1.8 weeks) (all p < 0.001). Dry macula rates increased from 39.6% to 70.7% (p < 0.001). Among treatment-naïve eyes, 74.4% achieved a dry macula at the last visit and 97.4% at the 4-week interval following induction. In eyes with ≥ 6 months of follow-up, the interval increased by +1.6 weeks and remained significant (p < 0.001). OCT biomarkers significantly decreased during follow-up (p < 0.001), while BCVA remained stable.Conclusions\n\nEarly real-world use of aflibercept 8 mg was associated with improved anatomical outcomes and extended treatment intervals in treatment-naïve and previously treated nAMD eyes, while maintaining stable BCVA and a favorable safety profile. These findings support its potential to reduce treatment burden in routine clinical practice.",
  "abstract_shown": true,
  "affiliations": [
    "Ophthalmology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, 103, Grande Rue de La Croix-Rousse, 69317, Lyon, France.",
    "MATEIS Laboratory, UMR-CNRS 5510, INSA, University of Claude, Bernard Lyon 1, 69100, Villeurbanne, France.",
    "UMF Iuliu Hațieganu, Cluj-Napoca, Romania.",
    "Centre Ophtalmologique Ophtarives, Geneva, Switzerland.",
    "Ophthalmology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, 103, Grande Rue de La Croix-Rousse, 69317, Lyon, France. laurent.kodjikian@chu-lyon.fr.",
    "MATEIS Laboratory, UMR-CNRS 5510, INSA, University of Claude, Bernard Lyon 1, 69100, Villeurbanne, France. laurent.kodjikian@chu-lyon.fr."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jules Fricker"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Lucas Sejournet"
    },
    {
      "affs": [
        0
      ],
      "name": "Jules Prange"
    },
    {
      "affs": [
        0
      ],
      "name": "Julien Andre"
    },
    {
      "affs": [
        0
      ],
      "name": "Remy Calvet"
    },
    {
      "affs": [
        0
      ],
      "name": "Valentin Rougane"
    },
    {
      "affs": [
        0
      ],
      "name": "Ségolène Gouze"
    },
    {
      "affs": [
        0
      ],
      "name": "Maxime Oudard"
    },
    {
      "affs": [
        0
      ],
      "name": "Ambre Ancel"
    },
    {
      "affs": [
        2
      ],
      "name": "Alexis Kodjikian"
    },
    {
      "affs": [
        2
      ],
      "name": "Simona Nicoara"
    },
    {
      "affs": [
        3
      ],
      "name": "Philippe Desmangles"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Thibaud Mathis"
    },
    {
      "affs": [
        4,
        5
      ],
      "name": "Laurent Kodjikian",
      "orcid": "0000-0002-3908-6716"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/08v5se72b2f4n.bib",
  "cited_by": 0,
  "doi": "10.1007/s40123-026-01510-1",
  "fulltext_url": "https://europepmc.org/articles/PMC13694659",
  "id": "08v5se72b2f4n",
  "issns": [
    "2193-8245",
    "2193-6528"
  ],
  "landing_url": "https://europepmc.org/article/MED/42832168",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RE1-994"
    ],
    [
      "openalex",
      "2731|Retinal Diseases and Treatments"
    ]
  ],
  "openalex": "W7220418225",
  "pdf_url": "https://europepmc.org/articles/PMC13694659?pdf=render",
  "pmcid": "PMC13694659",
  "pmid": "42832168",
  "published": "2026-10-05",
  "publisher": "Adis, Springer Healthcare",
  "ris": "https://research.draconitic.com/paper/08v5se72b2f4n.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:10Z",
      "native_id": "MED:42832168",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42832168"
    },
    {
      "first_seen": "2026-10-30T13:45:44Z",
      "native_id": "5c688d82252d4547a09f1ba9064f96f2",
      "source": "doaj",
      "url": "https://doi.org/10.1007/s40123-026-01510-1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2731|Retinal Diseases and Treatments",
      "subfield": "general"
    }
  ],
  "title": "Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.",
  "title_text": "Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:45:44Z",
  "url": "https://research.draconitic.com/paper/08v5se72b2f4n",
  "venue": "Ophthalmology and therapy",
  "versions": []
}